Fig. 4.
Overall survivals at 2 years of 165 patients who received cyclosporine/methotrexate, 57.2% (◊) and 164 patients who received tacrolimus/methotrexate 46.9% (□); absolute difference = 10.3%, 95% CI interval = −21.1 to 0.5 (P = .02, Wilcoxon).
Overall survivals at 2 years of 165 patients who received cyclosporine/methotrexate, 57.2% (◊) and 164 patients who received tacrolimus/methotrexate 46.9% (□); absolute difference = 10.3%, 95% CI interval = −21.1 to 0.5 (P = .02, Wilcoxon).
